ACZ885 + Placebo

Phase 2Terminated

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Abdominal Aortic Aneurysm (AAA)

Conditions

Abdominal Aortic Aneurysm (AAA)

Trial Timeline

Dec 1, 2013 → Oct 1, 2015

NCT ID

NCT02007252

About ACZ885 + Placebo

ACZ885 + Placebo is a phase 2 stage product being developed by Novartis for Abdominal Aortic Aneurysm (AAA). The current trial status is terminated. This product is registered under clinical trial identifier NCT02007252. Target conditions include Abdominal Aortic Aneurysm (AAA).

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02961218	Phase 2	Completed	Apr 5, 2017	Apr 27, 2020	Sickle Cell Anemia
NCT02888080	Phase 2	Completed	Dec 19, 2016	Mar 4, 2019	Pulmonary Sarcoidosis
NCT02007252	Phase 2	Terminated	Dec 1, 2013	Oct 1, 2015	Abdominal Aortic Aneurysm (AAA)
NCT01322321	Phase 2	Withdrawn	Mar 1, 2011	—	Diabetes Mellitus
NCT00995930	Phase 2	Completed	Dec 1, 2009	Feb 1, 2014	Diabetes Mellitus, Type 2
NCT00465985	Phase 3	Completed	Apr 1, 2007	—	Muckle Wells Syndrome

Competing Products

20 competing products in Abdominal Aortic Aneurysm (AAA)

See all competitors

Product	Company	Stage	Hype Score
PD-1 Inhibitors + Irinotecan + Capecitabine tablets	Jiangsu Hengrui Medicine	Phase 3	77
HR021618 + Placebo	Jiangsu Hengrui Medicine	Phase 2	52
Ticagrelor + Placebo	AstraZeneca	Phase 2	52
Relebactam 250 mg + Relebactam 125 mg + Imipenem/cilastatin + Matching placebo to relebactam	Merck	Phase 2	52
Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo	Merck	Phase 3	77
MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) + metronidazole 500 mg	Merck	Phase 3	77
CXA-201 and metronidazole + Meropenem	Merck	Phase 3	77
Imipenem+Cilastatin/Relebactam	Merck	Phase 3	77
CXA-101/ tazobactam and metronidazole + meropenem plus saline placebo	Merck	Phase 2	52
Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo for Metronidazole	Merck	Phase 2	52
Metformin Glucophage 500mg (IR) tablets M90 + Placebo Oral Tablet	Merck	Phase 2/3	65
Comparator: ceftriaxone sodium / Duration of Treatment: 8 Weeks + MK0826, /Duration of Treatment : 8 Weeks + Comparator: metronidazole / Duration of Treatment: 8 Weeks	Merck	Phase 3	77
MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazole	Merck	Approved	85
MK0826, /Duration of Treatment : 8 Weeks + Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 Weeks	Merck	Phase 3	77
LYS228 + Standard of care therapy	Novartis	Phase 2	52
Evolocumab + Placebo	Amgen	Phase 1	32
tigecycline	Pfizer	Phase 3	76
recombinant human growth hormone	Pfizer	Phase 3	76
Pregabalin 75 or 150 mg BID for 7 weeks followed by open label pregabalin 150 mg BID for 4 weeks + Placebo first followed by open label pregabalin	Pfizer	Approved	84
Ceftazidime-avibactam + metronidazole + Meropenem	Pfizer	Phase 3	76

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved